Loading
companiesCompany
Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)
The company behind devimistat, a drug against cancer cell metabolism that failed its phase 3 trials in pancreatic cancer and leukaemia.
Also called: Rafael Pharmaceuticals
Overview
Rafael Pharmaceuticals, majority owned by Rafael Holdings, developed devimistat (CPI-613) for pancreatic cancer and acute myeloid leukaemia. After both phase 3 trials missed their endpoints in 2021 and 2022 the company was renamed Cornerstone Pharmaceuticals and refocused its pipeline.
Headquarters
Cranbury, New Jersey, United States, US
Scorecard
All companies#413of 1244 companies, score 8
- modalities +2
- registry trials +9
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 21 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
NegativeSmall-molecule inhibitor of mitochondrial metabolism (PDH and KGDH)
Devimistat tried to starve pancreatic cancer cells of their energy supply alongside chemotherapy; the phase 3 AVENGER 500 trial found no survival gain.
Similar pages
cancers
drugs
NegativeSmall-molecule inhibitor of mitochondrial metabolism (PDH and KGDH)